Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 8,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Cancer Clear all
Terminated Phase 2 Interventional Results available

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

NCT01695330
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Subcutaneous bortezomib
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 1Phase 2 Interventional

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

NCT00016016
View directory record Official record
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, mitoxantrone hydrochloride, alvocidib, pharmacological study, laboratory procedure
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 30, 2026, 11:55 AM EDT
Active, not recruiting Not applicable Interventional

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

NCT05455606
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Best Practice, Chart Abstraction, Educational Intervention, Genomic Profile, Interview, Questionnaire Administration, Tumor Board Review
Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Phoenix, Arizona • Savannah, Georgia • Honolulu, Hawaii + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

NCT00570401
View directory record Official record
Conditions
Lung Cancer
Interventions
dasatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 30, 2026, 11:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03661307
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Quizartinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

NCT01338792
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
oxaliplatin, pemetrexed disodium, questionnaire administration, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, polymorphism analysis
Drug · Other · Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract

NCT00453336
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Interventions
Porfimer Sodium, Photodynamic Therapy
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 30, 2026, 11:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

NCT01918306
View directory record Official record
Conditions
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 30, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00290771
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme (GBM)
Interventions
Imatinib tablets, Hydroxyurea capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

NCT00083187
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
hydroxyurea, laromustine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 30, 2026, 11:55 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

NCT07000084
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
Biological · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

NCT00702884
View directory record Official record
Conditions
Esophageal Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Tony Bekaii-Saab
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 30, 2026, 11:55 AM EDT
Recruiting No phase listed Observational

Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy

NCT07214584
View directory record Official record
Conditions
Cervical Cancer, Human Papilloma Virus (HPV)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00824733
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, PF03512676, Correlative Studies
Drug · Other
Lead sponsor
Bhuvaneswari Ramaswamy
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Early Phase 1 Interventional

Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma

NCT04315064
View directory record Official record
Conditions
Medulloblastoma
Interventions
Treatment with MTX110
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 30, 2026, 11:55 AM EDT
Recruiting Phase 1 Interventional

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664
View directory record Official record
Conditions
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions
Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
Drug
Lead sponsor
Andrew E. Place, MD
Other
Eligibility
1 Year to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493
View directory record Official record
Conditions
Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer
Interventions
Venetoclax, Ibrutinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 30, 2026, 11:55 AM EDT
Terminated Not applicable Interventional

Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

NCT00966498
View directory record Official record
Conditions
High Risk Solid Tumors, Recurrent Solid Tumors
Interventions
Peripheral Blood Stem Cell Transplant
Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02756611
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 30, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00062387
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
perifosine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
12
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 30, 2026, 11:55 AM EDT
Withdrawn Phase 2 Interventional

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

NCT02811809
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, IHT
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

NCT01973309
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Vantictumab combined with paclitaxel
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 30, 2026, 11:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

NCT00981799
View directory record Official record
Conditions
Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Interventions
Nelarabine, Etoposide, Cyclophosphamide, Methotrexate, Filgrastim
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 30, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 30, 2026, 11:55 AM EDT